Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

6838.TW

STRONG SELLREMOVE

Formosa Pharmaceuticals, Inc. · Healthcare · Taiwan · $116M · Avg Vol: $135K/d

15
StockRank
Q
42
V
27
M
29
P/E (TTM)
—
ROE
-3.9%
D/E
0.0x
Dividend %
—
Director Trades · 180d
None in 180d →
Buybacks · 180d
None in 180d →
AI CONVICTION THESIS

Formosa Pharmaceuticals is a clinical-stage biopharmaceutical company. It lacks the established cash flows, high ROIC, and validated manufacturing scale of a high-quality CDMO, making it too speculative for our portfolio.

COMPANY DESCRIPTION

Formosa Pharmaceuticals, Inc. develops clinical-stage ophthalmic and oncology therapeutics, utilizing its proprietary APNT nanoparticle formulation platform. The company achieved FDA approval for its lead ophthalmic drug (APP13007) for post-operative ocular inflammation, validating its drug delivery technology. It is a clinical-stage biopharmaceutical company specializing in advanced nanoparticle-formulated therapeutics.

FINANCIAL SUMMARY (USD)

Year20212022202320242025CAGR
Revenue—41,5491.0M4.5M0.3M93.3%
EPS-0.13-0.12-0.08-0.05——
Shares—117.0M134.1M151.0M151.0M+29.1%
Debt—0.2M0.9M0.8M0.9M57.5%
Equity—14.8M36.0M48.9M46.0M46.1%
Op CF—-10.9M-6.2M-4.1M-3.0M—
Inv CF—-6.0M-21.4M-15.0M-2.2M—
Fin CF—17.7M31.6M19.7M-0.2M—
Loading...
PRICE (1Y)-10.0%
0.750.770.790.810.83May 12Jun 2Jun 23
SMA 50SMA 200
Close
$0.75
RSI (14)
18.2
52W High
$1.37
From 52W High
0.5%

SCORE BREAKDOWN

Quality
42
ROIC
-4.4%39.6
ROE
-3.9%40.4
GP/Assets
1.9%13.7
Op. Margin
-23.4%25.6
FCF/Assets
-7.9%31.0
Piotroski
316.1
Int. Cover
-50.0x6.0
D/E Ratio
0.02x84.1
Current Ratio
11.50x89.1
Value
27
P/E (TTM)
—N/A
EV/EBITDA
-23.4x25.0
P/FCF
—N/A
P/B
2.6x48.5
P/S
69.5x9.0
Div Yield
—N/A
Momentum
29
52W High %
55%34.4
RS 6M
-82%12.4
SMA 50/200
0.95x51.3
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
—N/A

FUNDAMENTALS

Market Cap
$116M
P/E (Forward)
—
Gross Margin
71.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 6838.TW are excluded.

TickerCompanyMkt CapStockRankSignal
6838.TWFormosa Pharmaceuticals, Inc.(you)$116M15STRONG SELL
6492.TWOSenhwa Biosciences, Inc.$121M17STRONG SELL
4178.TWStemCyte International, Ltd.$117M12STRONG SELL
6733.TWOBioGend Therapeutics Co., Ltd.$102M12STRONG SELL
4168.TWOGlycoNex Incorporation$91M17STRONG SELL
6657.TWEnergenesis Biomedical CO.,LTD.$101M8STRONG SELL
6794.TWUnicoCell Biomed Co., Ltd.$159M18STRONG SELL
4157.TWOTaiGen Biopharmaceuticals Holdings Limited$193M16STRONG SELL
6885.TWBRIM Biotechnology, Inc.$91M9STRONG SELL
MENSJyong Biotech Ltd.$121M4STRONG SELL

Peer medians: ROE 3.6% · P/E 16.2x · Gross margin 42.1%

Formosa Pharmaceuticals, Inc. (6838.TW) — Stock Score Summary

Formosa Pharmaceuticals, Inc. (6838.TW) has a MoatMap StockRank of 15/100 based on Quality (42/100), Value (27/100), and Momentum (29/100) factor scores. The current signal is STRONG SELL. Formosa Pharmaceuticals is a clinical-stage biopharmaceutical company. It lacks the established cash flows, high ROIC, and validated manufacturing scale of a high-quality CDMO, making it too speculative for our portfolio.

Formosa Pharmaceuticals, Inc. develops clinical-stage ophthalmic and oncology therapeutics, utilizing its proprietary APNT nanoparticle formulation platform. The company achieved FDA approval for its lead ophthalmic drug (APP13007) for post-operative ocular inflammation, validating its drug delivery technology. It is a clinical-stage biopharmaceutical company specializing in advanced nanoparticle-formulated therapeutics.

Key Financial Metrics

Price$0.75
Market Cap$116M
Price/Book2.62
Return on Equity-3.9%
Return on Invested Capital-4.4%
Debt/Equity1.76
Gross Margin71.0%
Operating Margin-23.4%
Revenue Growth7546.8%
Free Cash Flow$-163K

Formosa Pharmaceuticals, Inc. operates in the Biotechnology industry, part of the Healthcare sector (Taiwan).

Frequently Asked Questions

What is Formosa Pharmaceuticals, Inc.’s (6838.TW) StockRank?
MoatMap’s StockRank for Formosa Pharmaceuticals, Inc. (6838.TW) is 15/100, with a Strong Sell signal. It is a composite of Quality (42), Value (27), and Momentum (29) factor ranks across MoatMap’s 20,000+ stock universe.
Does Formosa Pharmaceuticals, Inc. have an economic moat?
Formosa Pharmaceuticals, Inc. (6838.TW) has a Quality factor score of 42/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Formosa Pharmaceuticals, Inc. a buy, hold, or sell?
MoatMap’s current signal for Formosa Pharmaceuticals, Inc. (6838.TW) is Strong Sell, based on a StockRank of 15/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Formosa Pharmaceuticals, Inc. in?
Formosa Pharmaceuticals, Inc. (6838.TW) operates in the Healthcare sector, specifically the Biotechnology industry (Taiwan).
Browse all ranked stocks6838.TW deep dive reportAI ChampionsHow we score stocksSense-check another stock